Valley Baptist-Harlingen to Hold Trauma Designation Reception

Breaking News
342

Translate to Spanish or other 102 languages!

Mega Doctor News 

- Advertisement -

Level II Trauma Designation is the first and only in the Rio Grande Valley

HARLINGEN – Valley Baptist Medical Center-Harlingen will hold a reception in recognition of its recent Major (Level II) Trauma Designation on Thursday, March 15 from 5 – 7 p.m. in the Valley Baptist-Harlingen Woodward Conference Center.

The hospital’s trauma center has been designated by the Texas Department of State Health Services as a Major (Level II) Trauma Facility. This follows the center’s verification by the American College of Surgeons after a review and visit last October. The Valley Baptist Medical Center-Harlingen trauma center is the first and only Major Trauma Facility in the Rio Grande Valley.

- Advertisement -

Presentations regarding the designation will begin at 6 p.m., and speakers will include Valley Baptist Health System & Valley Baptist-Harlingen CEO Manny Vela, Valley Baptist-Harlingen Trauma Medical Director Dr. Hillary Chollet, Harlingen Mayor Chris Boswell, and Harlingen Chamber of Commerce President & CEO Chris Gonzales.

For more information, call (956) 389-1953 or (956) 873-1378.

- Advertisement -
- Advertisement -

Latest news

- Advertisement -
Previous article
Medicine Students Get Head Start on Their Training with Flu Shots
Next article
Video: The Evolution of Heart Failure Treatment

More Articles

Embolism Treatment Developed at University of Michigan receives FDA clearance 

Patients with persistent blood clots require frequent medical interventions just to survive. Yet despite this critical need, there have been few advancements in how these patients are treated. 

FDA Approves Once-Weekly Generic Hormone Therapy Patch for Women

The U.S. Food and Drug Administration approved the first generic of Climara Pro (estradiol and levonorgestrel transdermal system, 0.045 mg per day/0.015 mg), a transdermal hormone therapy patch for women with an intact uterus applied once a week. The approval aligns with FDA’s Public Health Pillar: Increasing Access to Affordable Medicines & Medical Products.

FDA Approves Immunotherapy Regimen Studied by Mayo Clinic for Stage 3 Colon Cancer

The Food and Drug Administration (FDA) has approved the immunotherapy drug atezolizumab in combination with chemotherapy for some patients with stage 3 colon cancer following surgery. The treatment is for patients whose tumors have deficient DNA mismatch repair, or dMMR.

Texas Oncology Expands Cancer Care With New McAllen West Clinic

Texas Oncology celebrated the grand opening of its McAllen West clinic Sept. 29, expanding cancer treatment, diagnostic, and research capabilities in the Rio Grande Valley as the organization continues its presence in the region, spanning more than 40 years.
- Advertisement -